Parts of this article (those related to lack of effectiveness against the Omicron variant) need to be updated. Please help update this article to reflect recent events or newly available information.(January 2022)
Sarilumab
Monoclonal antibody
Type
Whole antibody
Source
Human
Target
IL-6R
Clinical data
Trade names
Kevzara
AHFS/Drugs.com
Monograph
MedlinePlus
a617032
License data
US DailyMed: Sarilumab
Routes of administration
Subcutaneous
ATC code
L04AC14 (WHO)
Legal status
Legal status
AU: S4 (Prescription only)
CA: ℞-only[2][3]
US: WARNING[1]Rx-only
EU: Rx-only
Pharmacokinetic data
Bioavailability
80%
Metabolism
likely proteases
Elimination half-life
21 days (steady-state, estimated)
Identifiers
CAS Number
1189541-98-7N
ChemSpider
none
UNII
NU90V55F8I
KEGG
D10161N
Chemical and physical data
Formula
C6388H9918N1718O1998S44
Molar mass
144164.28 g·mol−1
NY (what is this?)(verify)
Sarilumab, sold under the brand name Kevzara, is a human monoclonal antibody medication against the interleukin-6 receptor.[4] Regeneron Pharmaceuticals and Sanofi developed the drug for the treatment of rheumatoid arthritis (RA), for which it received US FDA approval on 22 May 2017 and European Medicines Agency approval on 23 June 2017.[5]
Development in ankylosing spondylitis has been suspended after the drug failed to show clinical benefit over methotrexate in a phase II trial.[6]
^"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
^"Arthritis". Health Canada. 8 May 2018. Retrieved 13 April 2024.
^"Regulatory Decision Summary for Kevzara". Drug and Health Products Portal. 12 January 2017. Retrieved 13 April 2024.
^"Statement On A Nonproprietary Name Adopted By The USAN Council: Sarilumab"(PDF). ama-assn.org. American Medical Association.
^"Kevzara: Authorisation details". European Medicines Agency. Retrieved 28 September 2017.
^"Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis". regeneron.com (Press release). Paris & Tarrytown, New York: Regeneron. July 12, 2011.
Sarilumab, sold under the brand name Kevzara, is a human monoclonal antibody medication against the interleukin-6 receptor. Regeneron Pharmaceuticals...
FDA in March 2017 and is reported to cost $37,000 per year. Kevzara (sarilumab injection) is an interleukin-6 (IL-6) receptor antagonist for treatment...
Pharmaceuticals. Jevtana (Cabazitaxel), for prostate cancer. Kevzara (Sarilumab), for blood tests, lung and prostate cancer, marketed by Regeneron. Libtayo...
rescue therapy in a patient with COVID-19 with no complete response to sarilumab". Infection. 48 (5): 767–771. doi:10.1007/s15010-020-01476-7. PMC 7340855...
Global Information
(what is this?) (verify)